Who’s Fault Is It Anyway?

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Behavioral and Social Issues Related to Accounting, Cost Accounting, Ethical Dilemma, Financial Accounting, Intermediate Accounting, Managerial Accounting, Uncategorized, Video Updates.

According to multiple sources, the popularity of Ozempic, (also known as semaglutide) isn’t rising due to increased rates of diabetes, but instead is being used by individuals as the new “weight loss wonder drug”.

Questions:

  1. Why is this a problem?
  2. Besides Ozempic, what other brands are available for the same drug?
  3. What does the term “off-label” mean and how does it usually impact the price a patient pays under his/her insurance plan?
  4. Largent-Phillips of Florida puts the blame of this crisis on the manufacturer and the supply chain. Do you agree?
  5. What is the connection between WeightWatchers and Ozempic-like drugs?

Source:

Lovelace, B., L. Dunn, K. Dahlgren. (2023). People with diabetes struggle to find Ozempic as it soars in popularity as a weight loss aid. NBC News.com, Jan. 12 (Retrievable online at https://www.nbcnews.com/health/health-news/people-diabetes-struggle-find-ozempic-soars-popularity-weight-loss-aid-rcna64916)

Meyersohn, N. (2023). WeightWatchers jumps into the prescription weight loss drug business. CNN.com, March 7 (Retrievable online at https://www.cnn.com/2023/03/07/business/weightwatchers-ozempic/index.html)

Smith, S. (2023). Ozempic’s weight loss side effect can make it harder to find for people with diabetes. NPR News, March 29 (Listen at https://www.wxxinews.org/npr-news).